340 related articles for article (PubMed ID: 24893041)
1. Unmet needs in the treatment of mantle cell lymphoma.
Rosen ST; Link BK; Fowler NH
Clin Adv Hematol Oncol; 2013 Nov; 11(11 Suppl 18):1-19. PubMed ID: 24893041
[TBL] [Abstract][Full Text] [Related]
2. Integrating emerging treatment options in mantle cell lymphoma.
Kahl BS; Fowler NH; Czuczman MS
Clin Adv Hematol Oncol; 2013 Dec; 11(12 Suppl 19):1-15. PubMed ID: 24893155
[TBL] [Abstract][Full Text] [Related]
3. Treatment strategies in mantle cell lymphoma.
Maddocks K; Blum KA
Cancer Treat Res; 2015; 165():251-70. PubMed ID: 25655613
[TBL] [Abstract][Full Text] [Related]
4. Current regimens and novel agents for mantle cell lymphoma.
Chen Y; Wang M; Romaguera J
Br J Haematol; 2014 Oct; 167(1):3-18. PubMed ID: 24974852
[TBL] [Abstract][Full Text] [Related]
5. Mantle cell lymphoma: 2013 Update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2013 Dec; 88(12):1082-8. PubMed ID: 24273091
[TBL] [Abstract][Full Text] [Related]
6. [Mantle cell lymphoma: Towards a personalized therapeutic strategy?].
Navarro Matilla B; García-Marco JA
Med Clin (Barc); 2015 Jun; 144(12):553-9. PubMed ID: 25023849
[TBL] [Abstract][Full Text] [Related]
7. [Mantle Cell Lymphoma - Cutting edge Dia-gnostics and Treatment Approaches].
Klener P; Trněný M
Klin Onkol; 2015; 28 Suppl 3():3S80-6. PubMed ID: 26489506
[TBL] [Abstract][Full Text] [Related]
8. [Current treatment strategy in mantle cell lymphoma].
Ogura M
Nihon Rinsho; 2014 Mar; 72(3):499-511. PubMed ID: 24724411
[TBL] [Abstract][Full Text] [Related]
9. Mantle cell lymphoma: 2012 update on diagnosis, risk-stratification, and clinical management.
Vose JM
Am J Hematol; 2012 Jun; 87(6):604-9. PubMed ID: 22615102
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy in mantle cell lymphoma: anti-CD20-based therapy and beyond.
Zhou Y; Zhang L; Romaguera J; Delasalle K; Han X; Du X; Kwak L; Yi Q; Wang M
Am J Hematol; 2008 Feb; 83(2):144-9. PubMed ID: 17722077
[TBL] [Abstract][Full Text] [Related]
11. The emerging role of lenalidomide in the management of mantle cell lymphoma (MCL).
Dawar R; Hernandez-Ilizaliturri F
Best Pract Res Clin Haematol; 2012 Jun; 25(2):185-90. PubMed ID: 22687454
[TBL] [Abstract][Full Text] [Related]
12. Refining the Mantle Cell Lymphoma Paradigm: Impact of Novel Therapies on Current Practice.
Avivi I; Goy A
Clin Cancer Res; 2015 Sep; 21(17):3853-61. PubMed ID: 26059189
[TBL] [Abstract][Full Text] [Related]
13. Phase I/II study of bortezomib-BEAM and autologous hematopoietic stem cell transplantation for relapsed indolent non-Hodgkin lymphoma, transformed, or mantle cell lymphoma.
William BM; Allen MS; Loberiza FR; Bociek RG; Bierman PJ; Armitage JO; Vose JM
Biol Blood Marrow Transplant; 2014 Apr; 20(4):536-42. PubMed ID: 24434781
[TBL] [Abstract][Full Text] [Related]
14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
Hagemeister FB
Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
[TBL] [Abstract][Full Text] [Related]
15. Bendamustine's emerging role in the management of lymphoid malignancies.
Rummel MJ; Gregory SA
Semin Hematol; 2011 Apr; 48 Suppl 1():S24-36. PubMed ID: 21530769
[TBL] [Abstract][Full Text] [Related]
16. [Current therapeutic strategies for mantle cell lymphoma].
Dreyling M; Schnaiter A; Schmidt C; Hoster E
Internist (Berl); 2016 Mar; 57(3):230-7. PubMed ID: 26886710
[TBL] [Abstract][Full Text] [Related]
17. Mantle Cell Lymphoma: First-line Therapy in Patients Not Eligible for Stem Cell Transplantation.
Nazeef M; Kahl BS
Curr Treat Options Oncol; 2015 Jun; 16(6):29. PubMed ID: 25975443
[TBL] [Abstract][Full Text] [Related]
18. Current treatment strategies in relapsed/refractory mantle cell lymphoma: where are we now?
Atilla E; Atilla PA; Demirer T
Int J Hematol; 2017 Mar; 105(3):257-264. PubMed ID: 27995456
[TBL] [Abstract][Full Text] [Related]
19. Mantle cell lymphoma: the promise of new treatment options.
Goy A; Kahl B
Crit Rev Oncol Hematol; 2011 Oct; 80(1):69-86. PubMed ID: 21168343
[TBL] [Abstract][Full Text] [Related]
20. Combined lenalidomide, low-dose dexamethasone, and rituximab achieves durable responses in rituximab-resistant indolent and mantle cell lymphomas.
Ahmadi T; Chong EA; Gordon A; Aqui NA; Nasta SD; Svoboda J; Mato AR; Schuster SJ
Cancer; 2014 Jan; 120(2):222-8. PubMed ID: 24122387
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
